Thoracic

Our multi-disciplinary approach

We discuss all lung cancer patients in a weekly multi-disciplinary meeting, attended by specialists from the departments of radiology, radiotherapy, pulmonology, nuclear medicine, (thoracic) surgery and pathology. For each patient, the team discusses the best treatment approach. If necessary, additional imaging and other diagnostics may be requested.

Most of our treatments can also be received at our treatment location in Emmen. For an optimal treatment, we will acquire a 4D-CT scan. This allows us to determine and take into account breathing-induced motion of the lungs and the tumor. During treatment delivery we regularly acquire cone-beam CTs to validate the accuracy of treatment delivery.

You can find more information about our treatment techniques here.

Proton therapy

As of January 2018 we offer proton therapy for selected indications. Proton therapy is not yet available for patients within the Thoracic Program. In the near future we may offer this treatment to selected patients.

Follow-up

We have an on-going follow-up program for all lung cancer patients who have received radiotherapy. At predetermined intervals, we contact patients by phone to track the late side-effects of the administered radiation therapy.

A. Bannink-Gawryszuk, MD, PhD

Specialisatie:
Lung tumors
Sarcomas

S.A. de Boer, MD, PhD

Specialization:
Lung tumors
Palliative lung tumors

O. Chouvalova, MD

Specialization:
Breast tumors
Lung tumors
Palliation

P. Deseyne, MD, PhD

Specialisatie:
Lung tumors
Breast tumors

J.F. Ubbels, MD

Specialization:
Lung tumors
Soft tissue tumors

R. Wijsman, MD

Specialization:
Lung tumors

The Thoracic Program participates in the following clinical trials and studies:

CLARIFY-studie (Inclusion of patients is closed)
With this study we investigate whether radiotherapy leads to increased blood pressure in the pulmonary artery and whether this affects heart function. We hope that in the future we will be able to better predict the risk of this side effect and to treat it.

SISTER study Phase 2
The goal of this research: to find out whether using breathing support during radiotherapy is well tolerated and whether this breathing support makes the lungs (and therefore the tumor) move less, making the radiation easier to give.

HYDOSE study
In this research, we are looking into whether a higher radiation dose with proton radiotherapy for stage 3 non-small cell lung cancer is safe and whether we see signs that it helps the tumor stay away more often and people live longer.

Dutch Cancer Registry

We share patient data with the Dutch Cancer Registry (NKR). They use this data for scientific research on cancer and its treatment. They cannot see who the data belongs to. More information about how this data is used can be found on the website of the Netherlands Comprehensive Cancer Organisation. Also, check out how we handle your data.